EHDN our joint path to clinical research


Prof. Dr. med. Jean-Marc Burgunder
Departments of Neurology,
Universities of
Bern (Switzerland)
Sichuan, Chengdu (China)
Central South, Changsha (China)
Sun Yat Sen, Guangzhou (China)

EHDN: together for progress



Riluzole in Huntington's Disease: A 3-Year, Randomized Controlled Study


G. Bernhard Landwehrmeyer, MD, PhD,¹ Bruno Dubois, MD,² Justo Garcia de Yébenes, MD,³ Berry Kremer, MD, PhD,⁴ Wilhelm Gaus, PhD,⁵ Peter H. Kraus, MD,⁶ Horst Przuntek, MD,⁶ Michel Dib, MD,² Adam Doble, PhD,⁷ Wilhelm Fischer, PhD,⁸ Albert C. Ludolph, MD, PhD,¹ and the European Huntington's Disease Initiative Study Group



Organisation



- Founded 2004
- Network
- Collaboration
 - HD researchers
 - HD clinicians
 - HD affected



EHDN



- A not-for-profit research organisation
- Committed to
 - advancing knowledge of HD
 - supporting the development of better therapeutic interventions
 - improving the quality of life of families affected by
 HD
- more than 2,000 members in 50 countries



Registry

- Multicentre (160), multilingual (13)
- Prospective observational study
- Participants (around 14000 up to 14 years)

Legacy database

EHDN: together for progress



executive committee



Advancing Research, Conducting Trials, Improving Care

Nine: elected by the

EHDN membership

executive committee




EUROPEAN
HUNTINGTON'S
DISEASE
NETWORK

Advancing Research, Conducting Trials, Improving Care

Nine: electe

EHDN membershi









executive committee



EUROPEAN
HUNTINGTON'S
DISEASE
NETWORK











Advancing Research, Conducting Trials, Improving Care

Scientific and bioethic advisory committee responsibilities

- Elected
- Advise members of the EHDN network
- recommendations to members EC





Central coordination



Language areas coordinators








Enroll-HD team




EHDN: together for progress





A Global Study





Enroll-HD



 A world wide clinical research platform and observational study for Huntington's disease

- has three main goals
 - better understand HD
 - improve the design of clinical trials
 - improve clinical care for HD patients

Enroll HD: Study Status



- Study sites: 147 active in 15 countries
 - North America
 - Latin America
 - Oceania
 - Europe
- Participants: 13,742 active participants (1.11.2017)




Support of Clinical trials

- Endorsement
 - EC, based on analysis of SBAC, CTTF,
 - Jointly with HSG
- Study preparation
 - Site evaluation
- Clinical site certification
- Study logistics
 - Contact with sites
 - Collaboration with clinical research organisation

Studies endorsed and supported

- Pridopidine (TEVA)
 - Pride HD
 - Open Pride
- Laquinimod (TEVA)
 - Legato
- PF-02545920 (PDE-10 Inhibitor) (Pfizer)
 - Amaryllis
 - Open Amaryllis
- Deep brain simulation
- Antisense oligonucleotides
 - IONIS
 - WAVE



EHDN scientific think tank

- Collect ideas
- Develop an interactive database
- Generate actions
- Follow-up













ABOUT HD

ABOUT EHDN

NEWS & EVENTS





ATHO CLINICIANS AND RESEARCHERS

CLINICAL TRIAL SPONSORS

The HD Science Think Tank An EHDN initiative to advance HD research THINK TANK PURPOSE Learn more WHO ARE WE? Learn more Learn more Learn more



Think Tank Purpose

The HD Science Think Tank is an EHDN initiative to advance HD research. Based on the 2017 Scientific Strategic Plan the HD Science Think Tank intends to complement other EHDN initiatives such as the Working Groups. The HD Science Think Tank engages with the HD research community in three different ways:

Working group:



EUROPEAN
HUNTINGTON'S
DISEASE
NETWORK

Advancing Research, Conducting Trials, Improving Care

Phenotype

- Motor phenotype
- Cognitive phenotype
- Behavioural phenotype
- Functional ability
- Quality of life
- Health economics

Pathophysiology

- Genetic modifiers
- Biological modifiers


Therapy

- Physiotherapy
- Invasive therapies

Task forces



- Driving
- Assessment of dysphagia
- Incidental findings in genetic studies
- Microbiome in HD





1 Hours

Motor Rater Training 2017

Learn how to conduct and score the UHDRS Motor Exam. Enroll-HD Motor Raters must complete certification on an annual basis.



1 Hours

Motor Rater Training 2016

Learn how to conduct and score the UHDRS Motor Exam. Enroll-HD Motor Raters must complete certification on an annual basis.



1 Hours

Cognitive Rater Training

Provides raters with guidance on the instructions for administering and scoring the Enroll-HD Cognitive Assessment Battery.



1 Hours

Behavioural Rater Training

PBA-s Teaching Video and the PBA-s Webinar Training materials, along with an introduction to the psychopathology of HD and



O 2 Hours

Functional Rater Training

Provides raters with training materials on how to administer and score the UHDRS Functional Scale.



1 2 Hours

HDCC Rater Training

Provides an introduction on how to administer and rate the onset of signs and symptoms that may or may not be related to HD using the HD Clinical Characteristics





O 2 Hours

Good Clinical Practice

The Barnett International Good Clinical Practices (GCP) training module provides teaching and assessment of GCP aimed at global clinical research











EUROPEAN



Education & Training

- Joint training activities
 - MDS-ES, ERN-RND, EHDN

- Fellowship Exchange Programme
 - Joint with MDS-ES



Plenary meeting



Thank you for being part of the EHDN2016 Plenary Meeting in The Hague!

See you in 2018!

EHDN

The Hague



Website



ABOUT HD ABOUT EHDN NEWS & EVENTS



Advancing Research, Conducting Trials, Improving Care

HD PATIENTS AND FAMILIES

HD CLINICIANS AND RESEARCHERS

CLINICAL TRIAL SPONSORS

Welcome to the

European Huntington's Disease Network

Our Mission

The EHDN is an independent nonprofit network dedicated to advancing research, conducting clinical trials and improving care for people affected by Huntington's disease. The network is comprised of clinicians, researchers and people affected by HD, working together to accomplish our mission.

LEARN MORE ABOUT EHDN

Newsletter





CHDI: aim



CHDI Foundation
Collaboration
developing therapies

substantially improve lives of individuals with HD

European Huntington Association



- Close collaboration
- Strong support for clinical trials and research
- Voice at the core
- Support of local activities

Other HD networks



- Mutual participation at meetings
- Joint trial evaluation
- Joint programs
- Regular leadership calls

Other HD networks



- Sharing of investigation protocols
- Collaborative work



中国亨廷顿病协作网2016成都会议

Chinese HD Network 2016 Chengdu Conference



ERN objectives





Facilitate improvements in access to diagnosis treatment provision of healthcare

Focal points for medical training research information dissemination evaluation.





Advancing Research, Conducting Trials, Improving Care

Background

Huntington's disease (HD) is a rare, dominantly inherited fatal neurodegenerative disease with worldwide prevalence caused by a single known gene mutation (*HTT* CAG-repeat expansion mutation).

The European Huntington's Disease Network (EHDN) was founded as a collaborative platform for health care professionals, researchers, people affected by HD and their relatives.

About EHDN

EHDN has > 2,000 members in 50 countries and ~ 160 study sites throughout Europe. Organisation:

- · Elected Executive Committee, supported by
- Elected Scientific and Bioethics Advisory Committee
- · Clinical Trial Task Force (CTTF-HD)
- Central Coordination (operations, science management, administration, IT)
- · Language Area Coordinators supporting their local study sites
- Working Groups



Our Mission

Advance knowledge of Huntington's disease, support the development of better therapeutic interventions and improve the quality of life of people affected by HD.

Our Strategy

Advancing Research

- · Collaboration of researchers, doctors, HD families
- Establish large cohort of HD participants with clinical data and biosample collection available for research¹
- Seed funding scheme to promote novel scientific ideas; grant manager to support grant applications
- Working groups: promote collaboration on key research questions in HD

Facilitating Clinical Trials

- CTTF-HD
- · Provide advice and support to industry partners.
- · Assist in feasibility assessment of trial sites.
- · Large patient databases (REGISTRY and Enroll-HD)
- · facilitate trial recruitment
- · data-mining to assist with trial design
- Site qualification and training
- Operational support by EHDN staff with in-depth HD knowledge and long-standing relationships with sites

Improving Clinical Care

- · Standardisation of care, sharing of best practice.
- · Information platform for patients and their relatives

Our Accomplishments

Research

 Longitudinal observational study (REGISTRY) with > 50 publications^{1,2}

REGISTRY (May 2017)	N
Countries	20
Sites	157
REGISTRY HD participants*	13,250
REGISTRY Controls	1,500
Biosamples (# individuals)	10,000

*> 87% 2 consecutive visits; ~50% with 5 visits over 5 years

Since 2013, transfer from REGISTRY to Enroll-HD, the first global HD observational study.

Eni

Clinical Trials

- Successful partnerships with industry in clinical trials^{3,4,5}
- Online rater training and certification
- Development of assessment tools
- · Rating scales available in all network languages

Care

- Standard of Care guidelines⁶
- · Contribution to international guidelines for predictive testing

References and contact


For general enquiries please contact: info@euro-hd.net

EHDN is supported by, and closely collaborates with, CHDI Foundation, Inc.



¹ GeM-HD, Cell, 2015; ² Orth et al, JNNP, 2011; ³ de Yebenes JG et al, Lancet Neurol., 2011; ⁴ Ferreira JJ et al, Mov. Disord., 2015;

⁵ Group HlotHS, EHDN, JAMA Neurol., 2013; ⁶ Neurodeg. Dis. Man., 2012, Vol 2, No 1





MDS Berlin 2016

EHDN in all of Europe NO FI SE RU LT BE PL DE CZ FR SK AT ΗU HR PT RO ES IT BG



Public relations



















EHDN: together for progress



Join!



ABOUT HD ABOUT EHDN NEWS & EVENTS

HD PATIENTS AND FAMILIES

HD CLINICIANS AND RESEARCHERS

CLINICAL TRIAL SPONSORS

About **EHDN**

The EHDN is a nonprofit research network committed to advancing research, facilitating the conduct of clinical trials, and improving clinical care in HD. Through the EHDN a platform has been created such that basic scientists, clinicians, patients and families can collaborate on academic and industry studies to fulfil its mission. The EHDN is supported by and collaborates closely with CHDI Foundation, Inc.

As a network of stakeholders in HD, the EHDN offers its members the opportunity to take a lead and propose, conduct and publish studies. Anyone who has an interest in HD, including those affected directly by the disease, may join the EHDN and, in so doing, make a personal contribution to HD events and research.

Want to join the EHDN?

Join!



ABOUT HD ABOUT EHDN NEWS & EVENTS



disease, may join the EHDN and, in so doing, make a to HD events and research.

Want to join the EHDN?

ADVANCING RESEARCH

CONDUCTING TRIALS

lead and propose, conduct and publish studies. Anyone who has an interest in HD, including those affected directly by the disease, may join the EHDN and, in so doing, make a personal contribution to HD events and research.

Want to join the EHDN?

